![5 big analyst AI moves: Google downgraded as Apple gets vote of confidence](https://i-invdn-com.investing.com/news/moved_small-LYNXNPEK3H0FI_L.jpg)
Please try another search
Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies patient immunoglobulin, and human coagulation factor. addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; and electronic product information consultation. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. was founded in 1993 and is based in Taiyuan, China.
Name | Age | Since | Title |
---|---|---|---|
Shaolan Fu | 82 | 2021 | Co-Chairman |
Li Yang | 53 | 2023 | Director |
Zuojun Dong | 54 | 2021 | Independent Director |
Xiaoying Huang | 50 | 2023 | Deputy GM & Non-Independent Director |
Hao Li | 52 | 2023 | Chairman |
Lan Ye | 45 | 2023 | Deputy GM & Non-Independent Director |
Hui Guo | 52 | 2023 | Chairman of the Supervisory Board |
Lei Yan | 33 | 2021 | Deputy GM & Director |
Wenqi Wang | 37 | 2023 | Independent Director |
Jun Yin | 69 | 2023 | Independent Director |
Wenbin Si | 43 | 2023 | Deputy GM & Non-Independent Director |
Wei Zheng | 49 | 2023 | Supervisor |
Chao Zuo | 38 | 2023 | Non-Employee Supervisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review